Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Gov't to Study Stronger Protection of NDA Data
July 7, 2003
- ADR Reports Hit Record High, Totaling 28,416 in FY2002
July 7, 2003
- Yamanouchi Fails to Report ADRs of Gaster 10 by Legal Deadline
July 7, 2003
- REGULATORY NEWS IN BRIEF
July 7, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 7, 2003
- Meet the Leaders (22)
July 7, 2003
- CORPORATE ROUNDUP NEWS IN BRIEF
July 7, 2003
- WORLD NEWS IN BRIEF
July 7, 2003
- NEW PRODUCTS
July 7, 2003
- Sankyo Reports Good Results with e-Promotion
July 7, 2003
- PRESS SEMINAR
July 7, 2003
- FJPWA Study Team Proposes Model PMS Manual
July 7, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
July 7, 2003
- BUSINESS NEWS IN BRIEF
June 30, 2003
- FPMAJ Committee Proposes Revisions to NHI Pricing Rules
June 30, 2003
- Business Challenges Discussed: UBS Conference
June 30, 2003
- Meet the Leaders (21)
June 30, 2003
- DIAGNOSTIC NEWS IN BRIEF
June 30, 2003
- MEDICAL DEVICE NEWS IN BRIEF
June 30, 2003
- OTC NEWS IN BRIEF
June 30, 2003
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…